Short title: Therapy-related MDS and AML after radioiodine treatment

[1]  Verena I Gaidzik,et al.  RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  K. Döhner,et al.  The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. , 2011, Blood.

[3]  A. Wölfler,et al.  Therapy‐related myeloid neoplasms: pathobiology and clinical characteristics , 2011, British journal of pharmacology.

[4]  D. Preston,et al.  Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Larson,et al.  Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia. , 2010, Chemico-biological interactions.

[6]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[7]  S. Acharya,et al.  Current and emerging treatment options for Graves’ hyperthyroidism , 2009, Therapeutics and clinical risk management.

[8]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[9]  S. Straus,et al.  Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. , 2009, Thyroid : official journal of the American Thyroid Association.

[10]  N. Kröger,et al.  Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation , 2009, Haematologica.

[11]  A. Hagemeijer,et al.  Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Larson,et al.  Therapy-related myeloid leukemia. , 2008, Seminars in oncology.

[13]  Rainer Haas,et al.  Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes , 2008, Annals of Hematology.

[14]  Rebeccah L. Brown.  Standard and emerging therapeutic approaches for thyroid malignancies. , 2008, Seminars in oncology.

[15]  F. Vathaire.  The carcinogenic effects of radioiodine therapy for thyroid carcinoma , 2008, Nature Clinical Practice Endocrinology &Metabolism.

[16]  Thomas H Müller,et al.  New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. , 2007, Blood.

[17]  U. Germing,et al.  Prognostic Factors in Treatment-Related Myelodysplastic Syndromes (t-MDS) and Acute Myeloid Leukemia (t-AML). , 2007 .

[18]  B. Ko,et al.  RUNX1 gene mutation in primary myelodysplastic syndrome – the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome , 2007, British journal of haematology.

[19]  M. Voso,et al.  Therapy-related leukemia and myelodysplasia: susceptibility and incidence , 2007, Haematologica.

[20]  D. Focosi,et al.  Acute myeloid leukemia and follicular lymphoma after very low dose radioiodine therapy for thyroid diseases , 2007, Haematologica.

[21]  T. Haferlach,et al.  A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. , 2007, Haematologica.

[22]  J. Grudeva-Popova,et al.  Therapy-related acute promyelocytic leukemia after treatment with radioiodine for thyroid cancer: case report with literature review. , 2007, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[23]  D. Christiansen,et al.  Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia , 2005, Leukemia.

[24]  J. Shay,et al.  Lack of mutations of the human telomerase RNA gene (hTERC) in myelodysplastic syndrome. , 2005, Haematologica.

[25]  P. Macpherson,et al.  Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. , 2004, Blood.

[26]  W. Hiddemann,et al.  Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML , 2004, Leukemia.

[27]  Sonali M. Smith,et al.  Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. , 2003, Blood.

[28]  P. Hall,et al.  Late consequences of radioiodine for diagnosis and therapy in Sweden. , 1997, Thyroid : official journal of the American Thyroid Association.

[29]  E. Estey,et al.  Treatment of therapy-related leukemia and myelodysplastic syndrome. , 1993, Hematology/oncology clinics of North America.

[30]  C. Edmonds,et al.  The long-term hazards of the treatment of thyroid cancer with radioiodine. , 1986, The British journal of radiology.

[31]  J. Fraumeni,et al.  Cancer incidence following treatment of hyperthyroidism. , 1982, International journal of epidemiology.